DrugPatentWatch Database Preview

Avapritinib - Generic Drug Details

« Back to Dashboard

What are the generic sources for avapritinib and what is the scope of patent protection?

Avapritinib is the generic ingredient in one branded drug marketed by Blueprint Medicines and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Avapritinib has thirty-four patent family members in twenty-seven countries.

Summary for avapritinib

International Patents:	34
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Bulk Api Vendors:	20
Clinical Trials:	4
Patent Applications:	6
DailyMed Link:	avapritinib at DailyMed

Recent Clinical Trials for avapritinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CStone Pharmaceuticals	Phase 1/Phase 2
Blueprint Medicines Corporation	Phase 1/Phase 2
Blueprint Medicines Corporation	Phase 2

See all avapritinib clinical trials

US Patents and Regulatory Information for avapritinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-002	Jan 9, 2020		RX	Yes	No			Y	Y
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-001	Jan 9, 2020		RX	Yes	No
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-002	Jan 9, 2020		RX	Yes	No
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-002	Jan 9, 2020		RX	Yes	No			Y	Y

International Patents for avapritinib

Country	Patent Number	Estimated Expiration
Taiwan	201546062
Croatia	P20181388
Spain	2683127
Taiwan	I683814